ArticleResearch and practice in thrombosis and haemostasis2024
Testing for the lupus anticoagulant: the good, the bad, and the ugly.
Article in Research and practice in thrombosis and haemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Design and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing.International journal of laboratory hematology · 2026Article
- [Thinking, evaluating, and replenishing the fibrinogen hemostatic strategy in neurosurgery].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- VEXAS Mimicking Antiphospholipid Syndrome: Diagnostic Challenges of False-Positive Antiphospholipid Antibodies.International journal of molecular sciences · 2026Article
- Comparison Between Chemiluminescent Assay and Enzyme-Linked ImmunoSorbent Assay Techniques for the Detection of Anti-Cardiolipin and Anti-β2 Glycoprotein I Antibody Values.Diagnostics (Basel, Switzerland) · 2026Article
- Biomarkers of Coagulation Disorders-Where to from Here?Biomolecules · 2026Review
- Normalization of activated partial thromboplastin time and diluted Russell's viper venom time ratios can be safely omitted in the assessment of lupus anticoagulant.Research and practice in thrombosis and haemostasis · 2026Article
- Laboratory Identification of Lupus Anticoagulant (LA) Using Different Activated Partial Thromboplastin Time (APTT) Assays.International journal of laboratory hematology · 2026Article
- Practical guide to management after an acute pulmonary embolism.BMJ open respiratory research · 2025Review
- Lupus Anticoagulant Testing for Diagnosis of Antiphospholipid Syndrome: A Perspective Informed by Local Practice.Journal of clinical medicine · 2025Article
- A Case of High-Risk Myelodysplastic Syndrome With Cryoglobulinemia, Hemophagocytic Lymphohistiocytosis, and Progression to Multiple Organ Failure.Journal of medical cases · 2025Article
- 1-Minute Pearls/Pitfalls for the Clinician.Journal of Brown hospital medicine · 2025Article
- Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing.Hematology. American Society of Hematology. Education Program · 2024Review
- Navigating the Complication: Acute Mastoiditis Causing Cerebral Venous Thrombosis in an Adult.Cureus · 2024Article
- Key Issues at the Forefront of Diagnosis and Testing for Antiphospholipid Syndrome.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus anticoagulant (LA) represents 1 of the laboratory criteria for classification of patients as having definite antiphospholipid syndrome (APS). The other 2 laboratory criteria are anticardiolipin antibodies and anti-beta2-glycoprotein I antibodies. At least 1 of these antiphospholipid antibody (aPL) tests need to be positive, with evidence of persistence, together with evidence of at least 1 clinical criterion for APS, before a patient can be classified as having definite APS. LA and other aPL assays are also important for diagnosis or exclusion of APS, as well as for risk stratification, with triple-positive patients carrying the greatest risk. Whereas LA is identified through "uncalibrated" clot-based assays, the other aPL assays (anticardiolipin and anti-beta2-glycoprotein I antibodies) represent immunological assays, identified using calibrated solid-phase methods. Because LA is identified using clot-based assays, it is subject to considerable preanalytical and analytical issues that challenge accurate detection or exclusion of LA. In this narrative review, we take a look at the good, the bad, and the ugly of LA testing, primarily focusing on the last 10 years. Although harmonization of LA testing as a result of International Society on Thrombosis and Haemostasis guidance documents and other international activities has led to improvements in LA detection, many challenges remain. In particular, several anticoagulants, especially direct oral anticoagulants and also vitamin K antagonists, given as therapy to treat the pathophysiological consequences of aPL, especially thrombosis, interfere with LA assays and can generate false-positive or false-negative LA findings. Overcoming these diagnostic errors will require a multifaceted approach with clinicians and laboratories working together.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.